Page 1

Press Release 27 July 2021 Results for the six months ended 30 June 2021 Record first half performance reflecting accelerated strategic implementation Croda International Plc ( " Croda " or the " Group " ) announces its half year results for the six months ended 30 June 2021 . This announcement contains inside information . Highlights Half year ended 30 June Sales ( £ m ) Operating profit ( £ m ) Return on sales ( % ) Profit before tax ( £ m ) Basic earnings per share ( p ) Ordinary dividend per share ( p ) Free cash flow ( £ m ) ● ● ● ● Record performance driven by accelerated strategic implementation Excellent underlying growth across all sectors O O O O Statutory results ( IFRS ) O 2021 934.0 218.5 O 204.1 110.0 43.5 O 2020 change 672.9 38.8 % 154.0 41.9 % 144.9 40.9 % 84.1 30.8 % 39.5 10.1 % 2021 934.0 242.1 25.9 229.5 124.0 42.7 Adjusted results Underlying sales up 27 % on 2020 , including successful raw material price recovery Sales now well above 2019 levels , up over 10 % in underlying terms ( before the benefit of lipid systems ) Strong Consumer Care and Performance Technologies performances , driven by end consumer recovery , customer inventory build and demand for sustainable solutions Benefitting from significant capital investment over last 12 months , together with increased innovation Successful delivery from recent acquisitions opening up new fast growth markets Iberchem profit performance in line with plan ; Avanti significantly ahead Integration and synergy delivery on track ; additional bolt - on acquisitions completed in Consumer Care Continued success in building Life Sciences platform 2020 change 672.9 38.8 % 161.6 49.8 % 24.0 190bps 152.5 50.5 % 88.8 39.6 % O Outstanding Health Care performance - continued sales growth of vaccine adjuvants and speciality excipients , supplemented by over US $ 100m of lipid system sales for COVID - 19 applications O Organic growth and acquisition resulting in near doubling of adjusted operating profit Over £ 40m invested in Health Care capacity expansion this half year , reinforcing leading niche positions Excellent first half financial results Reported sales up 39 % , driven by organic growth and acquisitions Improving margin driving excellent profit growth Return on sales up 190 basis points - Life Sciences performance supported by progress in Consumer Care and Performance Technologies Record adjusted profit before tax at £ 229.5m , up over 50 % on 2020 and 35 % on 2019 IFRS profit before tax up over 40 % to £ 204.1m ( 2020 : £ 144.9m ) Leverage reduced to 1.7x EBITDA , despite increased capital investment and demand - driven working capital build Interim ordinary dividend up 10 % to 43.5p , continuir unbroken trend of increasing returns nearly 30 years CRODA 80.2 ( 46.8 ) % change constant currency 46.9 % 58.7 % 59.5 % 48.0 % 1